Retatrutide side effects and fertility implications are increasingly searched topics as this investigational triple agonist advances through clinical trials. Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, producing pronounced effects on weight and blood glucose. Whilst Phase 2 data show a compelling efficacy signal, the drug remains unlicensed in the UK by the MHRA. Understanding its reported side effects — and what limited evidence exists regarding reproductive health — is essential for anyone considering trial participation or monitoring developments in this rapidly evolving area of obesity medicine.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously, producing greater weight reduction than single or dual agonists; it is not yet MHRA-licensed in the UK.

Retatrutide is an investigational injectable medication currently under clinical development for the treatment of obesity and type 2 diabetes. It belongs to a novel class of drugs known as triple agonists, meaning it simultaneously activates three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action distinguishes retatrutide from existing approved agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist).

By activating GLP-1 receptors, retatrutide is thought to promote insulin secretion, reduce appetite, and slow gastric emptying — effects that collectively contribute to improved blood glucose control and reductions in body weight. Activation of GIP receptors may further support fat metabolism and insulin sensitivity, whilst glucagon receptor agonism is believed to increase energy expenditure and promote the breakdown of stored fat (lipolysis). These proposed complementary actions are expected to produce a more pronounced effect on weight loss than single or dual receptor agonists, though the precise contribution of each receptor pathway in humans continues to be studied.

In a Phase 2 clinical trial published in 2023 in the New England Journal of Medicine (Jastreboff et al.), participants receiving the highest dose of retatrutide lost up to approximately 24% of their body weight over 48 weeks — a notably greater reduction than observed with currently approved agents. It is also worth noting that, consistent with other incretin-based and glucagon co-agonist therapies, small mean increases in heart rate were observed in the trial; this is a class-relevant finding that warrants monitoring in individuals with relevant cardiovascular history.

It is important to note that retatrutide has not yet received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains unavailable as a licensed treatment in the United Kingdom at this time.

Known and Reported Side Effects of Retatrutide

The most common retatrutide side effects are gastrointestinal — nausea, vomiting, diarrhoea, and constipation — which are dose-dependent, generally mild to moderate, and tend to resolve over time.

As with other drugs in the incretin-based therapy class, the most commonly reported side effects of retatrutide in clinical trials have been gastrointestinal in nature. These include:

• Nausea — the most frequently reported adverse effect, particularly during dose escalation

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite (which, whilst therapeutically intended, can occasionally be excessive)

• Abdominal discomfort or pain

These effects are generally dose-dependent and tend to be most pronounced during the initial weeks of treatment or when the dose is increased. In the Phase 2 trial, the majority of gastrointestinal side effects were mild to moderate in severity and resolved over time without requiring discontinuation of the drug.

Persistent vomiting or diarrhoea can lead to dehydration, which in turn may increase the risk of acute kidney injury — a class-relevant concern also noted in the Summary of Product Characteristics (SmPC) for approved GLP-1 receptor agonists such as semaglutide. Maintaining adequate fluid intake and seeking medical review if symptoms are prolonged is therefore important.

Beyond gastrointestinal symptoms, other adverse effects observed in trials include injection site reactions (such as redness, bruising, or mild swelling), fatigue, dizziness, and small mean increases in heart rate. Individuals with pre-existing cardiovascular conditions should discuss this with their clinician or trial team. There have also been signals — consistent with the broader GLP-1 receptor agonist class — relating to a potential increased risk of gallbladder-related conditions, such as cholelithiasis (gallstones), particularly in the context of rapid weight loss.

Preclinical rodent studies with GLP-1 class drugs have identified a potential risk of thyroid C-cell tumours (medullary thyroid carcinoma). The clinical relevance of this finding in humans is uncertain, and it is not established as a contraindication in UK Summaries of Product Characteristics for approved GLP-1 receptor agonists. Nevertheless, individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should seek specialist advice before using any drug in this class.

When retatrutide is used alongside insulin or sulfonylureas (relevant in the context of type 2 diabetes management), there may be an increased risk of hypoglycaemia; dose adjustments of the concomitant agent may be required.

As retatrutide's clinical programme continues to expand, the full safety profile will become clearer through larger and longer-duration studies. Patients who suspect they have experienced a side effect from any medicine — including those received as part of a clinical trial — are encouraged to report it via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk, in addition to informing their clinician or trial team.

What the Evidence Says About Retatrutide and Fertility

No direct human fertility data for retatrutide exist; indirect improvements in ovulatory function are plausible through weight loss, as seen with other GLP-1 agents in PCOS, but remain unconfirmed.

One area of growing patient interest concerns the potential impact of retatrutide on fertility. At present, there is no published, peer-reviewed evidence specifically examining the effects of retatrutide on human fertility — male or female. Because the drug remains in clinical development, long-term reproductive data are not yet available, and fertility outcomes were not a primary endpoint in the Phase 2 trials conducted to date.

However, it is reasonable to consider what is known from related drug classes. GLP-1 receptor agonists, including liraglutide and exenatide, have been associated in some studies with indirect improvements in fertility-related markers in women with obesity-related conditions such as polycystic ovary syndrome (PCOS) — for example, improvements in ovulatory function, androgen levels, and menstrual regularity. These benefits are thought to occur primarily through weight loss-mediated improvements in insulin sensitivity and hormonal balance, rather than any direct pharmacological effect on the reproductive system. Whether semaglutide specifically confers the same benefits is less well established, and any similar or enhanced indirect effects from retatrutide remain speculative in the absence of dedicated study data.

Of significant importance is the guidance applicable to the GLP-1 class regarding pregnancy planning. In the UK, washout periods before attempting conception are product-specific: for semaglutide, the SmPC advises discontinuation at least two months before a planned pregnancy; for tirzepatide, the SmPC advises at least one month. As retatrutide is not yet licensed, women of childbearing potential participating in trials should follow the contraception and discontinuation guidance specified in their trial protocol. GLP-1 receptor agonists are also not recommended during breastfeeding, in line with UK SmPC advice for approved agents in this class.

A further consideration for women using tirzepatide (and potentially other incretin therapies) is the possible reduction in exposure to oral contraceptives, particularly around initiation and dose escalation. The Faculty of Sexual and Reproductive Healthcare (FSRH) has issued guidance on this interaction; women should follow product-specific advice and consider additional barrier contraception where indicated. For retatrutide, the trial protocol should be followed.

It is also worth noting that rapid weight loss or very low energy availability can temporarily disrupt menstrual cycles in some individuals. However, for many women with obesity or PCOS, weight loss more commonly leads to improvement in cycle regularity. The overall effect will depend on individual circumstances. Anyone with concerns about fertility whilst using or considering retatrutide should seek personalised advice from their GP or a specialist.

When to Seek Medical Advice About Side Effects

Seek emergency care for anaphylaxis or severe breathing difficulty; contact a GP or trial team promptly for persistent vomiting, severe abdominal pain, or symptoms suggesting pancreatitis or gallbladder disease.

Because retatrutide is not yet licensed in the UK, individuals are unlikely to encounter it outside of a formal clinical trial setting. Nevertheless, understanding when to seek medical attention for side effects — whether from retatrutide or related approved medications — is an important aspect of patient safety.

Call 999 or go to your nearest A&E immediately if you experience:

• Signs of a serious allergic reaction (anaphylaxis), including facial or throat swelling, difficulty breathing, a rapid heartbeat, or a widespread rash — this is a medical emergency

• Severe difficulty breathing or collapse

Contact your GP, NHS 111, or your trial medical team promptly if you experience:

• Persistent or severe vomiting or diarrhoea that prevents adequate fluid or food intake; this can lead to dehydration and, in some cases, acute kidney injury — maintain fluid intake and seek review if symptoms are prolonged or you notice reduced urine output or dizziness

• Severe abdominal pain, particularly if it radiates to the back or is accompanied by vomiting — this may indicate pancreatitis, a rare but serious adverse effect associated with the GLP-1 drug class; if pancreatitis is suspected, the medicine should be stopped immediately and medical assessment sought; it should not be restarted if pancreatitis is confirmed

• Symptoms of gallbladder problems, such as upper right abdominal pain, fever, or jaundice (yellowing of the skin or eyes)

• A lump or swelling in the neck, hoarseness, or difficulty swallowing, which could indicate thyroid abnormalities — seek specialist advice

• Symptoms of low blood sugar (hypoglycaemia) if also taking insulin or a sulfonylurea, such as shakiness, sweating, confusion, or palpitations

• A notable or sustained increase in heart rate without an obvious cause

• Significant changes to your menstrual cycle or unexpected symptoms that may relate to reproductive health

Use NHS 111 (online at 111.nhs.uk or by telephone) when you need urgent medical advice and your GP or trial team is not immediately available.

For those participating in a clinical trial, all adverse effects — even those that seem minor — should be reported to the trial team as part of the pharmacovigilance process. This reporting is essential for building the safety evidence base that regulators such as the MHRA rely upon when assessing new medicines. Suspected side effects from any medicine can also be reported directly via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

If you are taking an approved GLP-1 receptor agonist and are planning a pregnancy, discuss this with your GP or specialist well in advance to allow adequate time to safely discontinue the medication before conception, in line with the product-specific guidance in the relevant SmPC.

Current MHRA and NICE Guidance on Retatrutide in the UK

Retatrutide holds no MHRA marketing authorisation and is unavailable on the NHS; UK use is restricted to approved clinical trials, with no confirmed timeline for regulatory submission announced.

As of the time of writing, retatrutide has not been granted a marketing authorisation by the MHRA and is therefore not a licensed medicine in the United Kingdom. It is not available through NHS prescribing, nor has it been assessed by the National Institute for Health and Care Excellence (NICE) for use in clinical practice. Any use of retatrutide in the UK is currently restricted to participants enrolled in approved clinical trials operating under strict ethical and regulatory oversight.

The MHRA regulates the approval of new medicines in Great Britain following the UK's departure from the European Union, whilst the EMA retains responsibility for authorisation across EU member states. Both agencies require robust evidence of safety, efficacy, and quality before granting a licence. Retatrutide's developer, Eli Lilly, is expected to progress to Phase 3 trials, and regulatory submissions may follow in due course — though no confirmed timeline for UK approval has been announced. The regulatory and trial status of retatrutide may change; readers should check current sources for the latest information.

In the meantime, NICE has issued guidance on existing licensed weight management medications. Semaglutide 2.4 mg (Wegovy) has received a NICE Technology Appraisal recommendation for use in adults with obesity under specific criteria (NICE TA875). Tirzepatide (Mounjaro) has been recommended by NICE for the treatment of type 2 diabetes in adults (NICE TA924) and has also been assessed in the context of weight management. These approvals provide a useful regulatory framework and signal the direction of travel for future agents such as retatrutide.

Patients interested in weight management options should speak with their GP, who can advise on currently available, evidence-based treatments through the NHS. Participation in legitimate clinical trials can be explored via the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or the ClinicalTrials.gov registry. It is strongly advised to avoid purchasing retatrutide from unregulated online sources, as such products carry serious risks of contamination, incorrect dosing, and unknown safety profiles.

This article was last reviewed for accuracy against available published evidence and UK regulatory guidance at the time of publication. Readers should check for updates as the evidence base and regulatory status of retatrutide continue to evolve.

Frequently Asked Questions